Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

1880 - A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN


10 Oct 2016


Immunotherapy of cancer


David Hong


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


D. Hong1, G. Falchook2, C.E. Cook3, W. Harb4, P. Lyne5, P. McCoon6, M. Mehta3, P. Mitchell7, G.M. Mugundu8, M. Scott3, J.S. Wang9

Author affiliations

  • 1 Investigational Cancer Therapeutics, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Drug Development, Sarah Cannon Research Institute at HealthONE, 80218 - Denver/US
  • 3 Early Clinical Development, AstraZeneca Pharmaceuticals, Waltham/US
  • 4 Horizon Oncology Center, Unity Campus, Lafayette/US
  • 5 Oncology Imed, AstraZeneca Pharmaceuticals, Waltham/US
  • 6 Translational Science, AstraZeneca Pharmaceuticals, Waltham/US
  • 7 Early Clinical Biometrics, AstraZeneca Pharmaceuticals, Waltham/US
  • 8 Qunatitative Clinical Pharmacology, Early Clinical Development, AstraZeneca Pharmaceuticals, Waltham/US
  • 9 Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota/US


Abstract 1880


Activating the immune system for therapeutic benefit in cancer has long been a goal in immunooncology. Combining a PD-L1 antagonist, durvalumab (D), with novel agents targeting immunosuppression in the tumor bed such as AZD9150 (A9, an antisense oligonucleotide against STAT3) or AZD5069 (A5, a CXCR2 antagonist) may strongly enhance anti-tumor responses.


Patients (pts) with advanced solid malignancies (N = 31) were enrolled using a CRM–based approach to identify dose combinations of A9 + D and A5 + D with an incidence of dose-limiting toxicities (DLT) less than 33%. Up to 6 evaluable pts per cohort were initially assessed. For all, D was fixed at 20 mg/kg Q4W with A9 at dose levels (DL) of (1) 2mg/kg QW or (2) 3mg/kg QW i.v; A5 was started at DL1 40 mg po bid, then DL2 80 mg bid. The primary objective was to determine the MTD and recommended phase II dose (RP2D), and secondarily safety, PK, pharmacodynamics, biological and clinical activity for each combination.


In the A9 + D arm, 11 pts (DL1 = 4, DL2 = 7) were treated. The most common drug related adverse events (AEs) were thrombocytopenia (64%), neutropenia (45%) and ALT/AST increase (36%) with no DLTs or drug-related Gr 4 events. The MTD/RP2D for AZD9150 was 3 mg/kg QW. In the A5 + D arm, 20 pts were enrolled (DL1 = 9; DL2 = 11) with most common drug related AEs of neutropenia (35%), fatigue or anorexia (20%). One DLT of Gr 3 neutropenia occurred at 40 mg bid; 2 similar DLTs were noted at DL2. The MTD/RP2D for AZD5069 was 40 mg po bid. Two pts in the A9 + D arm achieved a confirmed PR (MSH2/6 mutant mCRPC, GE jxn tumor) per modified iRECIST. Three more pts on A9 + D (laryngeal, colorectal, leiomyosarcoma) and two on A5 + D (breast, urothelium) demonstrated stable disease; the last pt's course was clearly consistent with pseudoprogression. Target engagement was shown in peripheral blood of A9 + D (STAT3 knockdown) and A5 + D (CXCR2-elicited cytokines) pts.


Combinations of durvalumab with AZD9150 or AZD5069 have a manageable toxicity profile and encouraging evidence of activity. Enrollment into phase 2 SCCHN expansion cohorts continues. Pharmacokinetic and pharmacodynamic data will be presented.

Clinical trial identification


Legal entity responsible for the study

AstraZeneca Pharmaceuticals LP


AstraZeneca Pharmaceuticals LP


D. Hong, G. Falchook, W. Harb, J.S. Wang: Research funding for clinical trials from AstraZeneca. C.E. Cook: AstraZeneca employee and stock holder. P. Lyne, P. McCoon, M. Mehta, P. Mitchell, M. Scott, G.M. Mugundu: Employee of AstraZeneca Pharmaceuticals LP.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings